Knowing Plasma Concentrations Improves Management of the Effects of Dabigatran  by Stöllberger, Claudia & Finsterer, Josef
J A C C V O L . 6 4 , N O . 8 , 2 0 1 4 Letters
A U G U S T 2 6 , 2 0 1 4 : 8 4 5 – 9
847received research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai,
Ethicon, Medtronic, Sanoﬁ-Aventis, and The Medicines Company; and un-
funded research from FlowCo, PLx Pharma, and Takeda. Dr. Steg has received
research grants through Unité INSERM U-1148 from Sanoﬁ-Aventis and Servier;
has consulted with and served as speaker for Amarin, AstraZeneca, Bayer,
Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi-Sankyo, GlaxoSmithKline,
Iroko Cardio, Lilly, Merck, Novartis, Otsuka, Pﬁzer, Sanoﬁ, Servier, The Medi-
cines Company, and Vivus; and is a stockholder in Aterovax. All other authors
have reported they have no relationships relevant to the contents of this paper
to disclose.
RE F E RENCE S
1. Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering
and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes
Trial. Eur Heart J 2006;27:2982–8.
2. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary
disease events in subgroups deﬁned by coronary risk factors: the Prospective
Pravastatin Pooling Project. Circulation 2000;102:1893–900.
3. Bangalore S, Steg G, Deedwania P, et al. b-Blocker use and clinical out-
comes in stable outpatients with and without coronary artery disease. JAMA
2012;308:1340–9.
4. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition,
and treatment of cardiovascular risk factors in outpatients with athero-
thrombosis. JAMA 2006;295:180–9.
5. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year
cardiovascular event rates in stable outpatients at risk of or with athero-
thrombosis. JAMA 2010;304:1350–7.Knowing Plasma
Concentrations Improves
Management of the
Effects of DabigatranWith interest we read the report by Reilly et al. (1) in a
recent issue of the Journal regarding the effect of
dabigatran plasma concentrations and patient char-
acteristics on the frequency of ischemic stroke and
major bleeding in patients with atrial ﬁbrillation. We
have the following comments and concerns.
Dabigatran is a substrate of the P-glycoprotein
system (P-gp). Many drugs are known to inhibit or
induce the activity of P-gp (2). Was there any associa-
tion between comedication of drugs affecting P-gp
activity and plasma concentrations of dabigatran? It
is known that P-gp activity is dependent on poly-
morphisms (3). Did the authors investigate the preva-
lence of P-gp polymorphisms and its association with
dabigatran levels?
Because metabolization of a substance also de-
pends on diurnal rhythms, it would be interesting to
know if the samples were all taken at the same time of
the day. Renal function may deteriorate over time,
especially in elderly patients, due to comorbidities.
Did the authors observe an increase of plasma dabi-
gatran levels in patients whose renal function deteri-
orated over time?Were the plasma levels of dabigatran
correlated with renal function? What was the optimalrange of dabigatran to prevent both ischemia and
bleeding?
Table 2 in the report by Reilly et al. (1) shows that
dabigatran plasma concentrations were higher in
patients 75 years of age or older, but no data are given
for patients older than 80 years of age. Because many
patients with atrial ﬁbrillation are older than 80 years
of age, it would be interesting to analyze the results in
this subgroup of patients more precisely.
What was the time interval between measurement
of the dabigatran level and occurrence of the bleeding
or ischemic event? Did patients with higher levels
develop bleeding earlier than patients with lower
levels, and did patients with low levels develop
ischemic events earlier than patients with higher
levels? Were there any patients in whom plasma
dabigatran levels were investigated at the time when
the bleeding or ischemic event occurred? Was the
volume of the bleeding or the size of the ischemic
stroke correlated with the dabigatran levels?
The authors report only the association of plasma
dabigatran levels with major bleeding. It would be of
interest to know if this association was also found in
patients with minor bleeding.
In the discussion, it is mentioned that an assay of
dabigatran concentration is not yet available. When
will this assay be available?
The RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) study was published in
2009. Since that time, the drug has been used
in thousands of patients, and many bleeding and
ischemic episodes have been reported outside clinical
trials (4). Whywere the results of the present study not
reported sooner than 5 years after publication of the
RE-LY study? Knowledge of the importance of dabi-
gatran levels would have saved some of these patients.
Overall, this study provides evidence that preven-
tion of ischemic stroke by dabigatran is dependent on
the plasma concentration of the drug and cannot be
managed simply by using 2 different types of dosages.
There is a strong need to determine the dose of this
drug according to the plasma concentration and to ﬁnd
the optimal plasma concentration that best prevents
the recurrence of stroke but also the occurrence of a
bleeding event.*Claudia Stöllberger, MD
Josef Finsterer, MD, PhD
*Krankenanstalt Rudolfstiftung
Steingasse 31/18
A-1030 Vienna
Austria
E-mail: claudia.stoellberger@chello.at
http://dx.doi.org/10.1016/j.jacc.2014.04.074
Letters J A C C V O L . 6 4 , N O . 8 , 2 0 1 4
A U G U S T 2 6 , 2 0 1 4 : 8 4 5 – 9
848RE F E RENCE S
1. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma con-
centrations and patient characteristics on the frequency of ischemic stroke and
major bleeding in atrial ﬁbrillation patients: the RE-LY Trial (Randomized
Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63:
321–8.
2. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport
system and cardiovascular drugs. J Am Coll Cardiol 2013;61:2495–502.
3. Ieiri I. Functional signiﬁcance of genetic polymorphisms in P-glycoprotein
(MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug
Metab Pharmacokinet 2012;27:85–105.
4. McConeghy KW, Bress A, Qato DM, Wing C, Nutescu EA. Evaluation of dabi-
gatran bleeding adverse reaction reports in the FDA Adverse Event Reporting
System during the ﬁrst year of approval. Pharmacotherapy 2014;34:561–9.MicroRNA-29a Is a
Friend or Foe for
Cardiac Hypertrophy?MicroRNAs (miRNAs) play an important role in the
pathogenesis of structural alterations of cardiac hy-
pertrophy (1). However, the precise mechanisms of
miRNA-29a in cardiac hypertrophy are still unclear.
A recent report in the Journal by Roncarati et al. (2)
indicated that correlation with left ventricular hy-
pertrophy parameters holds true for only miRNA-
29a, which is signiﬁcantly associated with both
cardiac hypertrophy and ﬁbrosis. This suggests that
miRNA-29a is a potential therapeutic target for car-
diac hypertrophy.
Other studies have found that down-regulation of
miRNA-29a is associated with pathological cardiac
hypertrophy. Abonnenc et al. (3) showed that levels
of miRNA-29a were signiﬁcantly reduced in a mouse
model of pathological but not physiological hyper-
trophy (3). Furthermore, Divakaran et al. (4) indi-
cated that Smad3 signaling plays dual roles in the
heart: a beneﬁcial role by delimiting hypertrophic
growth and a deleterious role by modulating myo-
cardial ﬁbrosis, possibly through a pathway that en-
tails accumulation of miRNA-29a, which decreases
collagen gene expression. However, Zile et al. (5)
showed that miRNA-29a levels increased 5 days after
myocardial infarction and then decreased to control
levels at later time points. A time-dependent change
in miRNA-29a levels occurred in patients
with myocardial infarction, including an early and
robust increase in miRNA levels that affected myo-
cardial ﬁbrosis.
These ﬁndings suggest that miRNA-29a may be
a good clinical biomarker for patients with cardiac
hypertrophy because it seems to play a key role in
the development of this condition. Additional studieswith more patients and animal studies are needed
to determine the precise role of miRNA-29a in car-
diac hypertrophy, and therapeutic agents targeting
miRNA-29a might result in innovative new therapies.
All in all, we greatly enjoyed reading the article by
Roncarati et al. (2) and believe that miRNA-29a may
be useful for the prevention and treatment of cardiac
hypertrophy.Hui Tao, MD
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Interleukin Genotypes
Potentiate Early and
Advanced Atherosclerosis
DifferentlyWe read with interest the paper by Tsimikas et al.
(1) in a recent issue of the Journal, which reported
that genetic differences in the interleukin (IL)-1 gene
cluster, known to be associated with inﬂammatory
responsiveness, strongly inﬂuence the presence of
